Propranolol for Akathisia
Propranolol is an effective treatment option for akathisia, but it should NOT be used as first-line therapy—instead, prioritize dose reduction of the offending antipsychotic or switching to a lower-risk agent (e.g., quetiapine or olanzapine) before adding propranolol. When pharmacological rescue is necessary and dose adjustment isn't feasible, propranolol represents one of the best-supported adjunctive options alongside mirtazapine 1, 2.
When to Use Propranolol
Propranolol becomes appropriate when:
- Dose reduction of the causative antipsychotic is not feasible due to inadequate symptom control
- Switching antipsychotics is not practical in the clinical context
- Akathisia persists despite initial management attempts 1, 2
The 2025 INTEGRATE guidelines explicitly state that akathisia can be managed with dose reduction or switching to quetiapine/olanzapine as preferred strategies, with adjunctive propranolol as an alternative 1. The 2020 APA guidelines similarly recommend dose reduction or switching before adding adjunctive agents 2.
Dosing Guidelines
Start with 10 mg two to three times daily, with a maximum of 30 mg two to three times daily 1. More specifically:
- Starting dose: 10-20 mg/day
- Typical effective range: 20-80 mg/day (divided doses)
- Maximum dose: Up to 90 mg/day (30 mg three times daily)
- Response time: Rapid—most patients respond within 24 hours 3
The evidence shows that relatively low doses (30-80 mg/day) are sufficient for akathisia management, with complete remission achieved in approximately 64% of patients (9 of 14) in open trials 3. Controlled trials confirm significant improvement in both subjective and objective akathisia ratings 4.
Evidence Quality
A 2024 network meta-analysis found propranolol (20 mg/day for ≥6 days) demonstrated moderate efficacy compared to placebo (SMD -0.78; 95% CI -1.35 to -0.22), though it ranked below mirtazapine, biperiden, and vitamin B6 in overall effectiveness 5. However, sensitivity analyses showed some variability in propranolol's effect, suggesting it may not be as robust as other options 5.
The mechanism appears to involve beta-1 adrenoceptor blockade, as betaxolol (a selective beta-1 blocker) showed equivalent efficacy to propranolol in controlled trials 6.
Absolute Contraindications
Do not use propranolol in patients with 7:
- Cardiogenic shock
- Sinus bradycardia or heart block greater than first-degree
- Bronchial asthma
- Known hypersensitivity to propranolol
Critical Pitfall: Propranolol-Aripiprazole Interaction
AVOID propranolol during aripiprazole treatment—this is a crucial clinical caveat. A 2025 study found that propranolol comedication significantly increased akathisia risk during aripiprazole treatment (38.5% vs 5.9% in controls; OR=7.6) 8. This paradoxical effect likely occurs because propranolol inhibits CYP2D6, elevating aripiprazole plasma concentrations and worsening akathisia 8.
If a patient on aripiprazole develops akathisia, choose alternative agents (benzodiazepines, anticholinergics, or mirtazapine) rather than propranolol.
Alternative Agents
When propranolol is contraindicated or ineffective, consider:
- Mirtazapine (15 mg/day)—highest efficacy in network meta-analysis 5
- Benzodiazepines (e.g., clonazepam) 2
- Anticholinergics (e.g., biperiden 6 mg/day) 2, 5
- Vitamin B6 (600-1200 mg/day)—excellent efficacy and tolerance profile 5
The mnemonic "B-CALM" (Beta-blockers, Clonazepam, Anticholinergics, cLonidine, Mirtazapine) helps recall evidence-based options 9.
Monitoring
No specific monitoring beyond standard vital signs is required for propranolol at these low doses. Response should be evident within 24-48 hours 3. If no improvement occurs within several days, consider switching to an alternative agent rather than escalating the dose beyond 80-90 mg/day.